Dr. Shah is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1515 Holcombe Blvd
Houston, TX 77030Phone+1 713-792-6161- Is this information wrong?
Education & Training
- University of Alabama Medical CenterFellowship, Hematology and Medical Oncology, 2004 - 2007
- Cleveland Clinic FoundationResidency, Internal Medicine, 2001 - 2004
- Ohio State University College of MedicineClass of 2001
Certifications & Licensure
- TX State Medical License 2007 - 2025
Clinical Trials
- Lenalidomide, Thalidomide and Dexamethasone in Treating Participants With Relapsed or Refractory Multiple Myeloma Start of enrollment: 2009 Aug 25
- Panobinostat and Carfilzomib in Treating Participants With Relapsed or Refractory Multiple Myeloma Start of enrollment: 2011 Jul 28
- Filanesib and Carfilzomib in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia Start of enrollment: 2012 Feb 24
- Join now to see all
Publications & Presentations
PubMed
- 15 citationsEffect of Age and Frailty on the Efficacy and Tolerability of Once-Weekly Selinexor, Bortezomib, and Dexamethasone in Previously Treated Multiple MyelomaHolger W. Auner, Maria Gavriatopoulou, Sosana Delimpasi, Maryana Simonova, Ivan Spicka, Ludek Pour, Meletios A. Dimopoulos, Iryna Kriachok, Halyna Pylypenko, Xavier Le...> ;American Journal of Hematology. 2021 Mar 23
- 4 citationsPhase 1 Trial Evaluating Vorinostat Plus Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple MyelomaJonathan L. Kaufman, Roberto Mina, Jatin J. Shah, Jacob P. Laubach, Ajay K. Nooka, Colleen Lewis, Charise Gleason, Cathy Sharp, R. Donald Harvey, Leonard T. Heffner, P...> ;Clinical Lymphoma, Myeloma & Leukemia. 2020 Jul 25
- 5 citationsPhase I/Ib study of carfilzomib and panobinostat with or without dexamethasone in patients with relapsed/refractory multiple myeloma.Elisabet E. Manasanch, Jatin J. Shah, Hans C. Lee, Donna M. Weber, Sheeba K. Thomas, Behrang Amini, Jasper B. Olsem, Brandon N. Crumpton, Ashley Morphey, Zuzana Berkov...> ;Haematologica. 2020 May 1
- Join now to see all
Abstracts/Posters
- Response to Therapy and the Effectiveness of Treatment with Selinexor and Dexamethasone in Patients with Penta-Exposed Triple-Class Refractory Myeloma Who Had Plasmacy...Jatin Shah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Influence of Cytogenetics in Patients with Relapsed Refractory Multiple Myeloma Treated with Oral Selinexor and Dexamethasone: A Post-Hoc Analysis of the STORM StudyJatin Shah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Overall Survival of Triple Class Refractory, Penta-Exposed Multiple Myeloma (MM) Patients Treated with Selinexor Plus Dexamethasone or Conventional Care: A Combined An...Jatin J. Shah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Join now to see all
Lectures
- Selinexor Plus Pomalidomide and Low Dose Dexamethasone (SPd) in Patients with Relapsed or Refractory Multiple Myeloma2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Single Agent Oral Selinexor Demonstrates Deep and Durable Responses in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) in Both GCB and Non-GCB Subtypes: The ...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Updated Results of a Phase II Study of Lenalidomide-Elotuzumab As Maintenance Therapy Post-Autologous Stem Cell Transplant (AuSCT) in Patients (Pts) with Multiple Myel...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
- Sumitomo Pharma Oncology Receives Orphan Drug Designation for TP-1287, an Investigational Oral CDK9 Inhibitor for the Treatment of Ewing SarcomaApril 10th, 2023
- Sumitomo Pharma Oncology Receives Orphan Drug Designation for TP-3654, an Investigational Oral Inhibitor of PIM Kinases for the Treatment of MyelofibrosisJune 8th, 2022
- Rakesh Roshan on His Battle with Cancer: I Was Sure I Had Cancer Even Before the Reports CameOctober 19th, 2019
- Join now to see all
Hospital Affiliations
- University of Texas M.D. Anderson Cancer CenterHouston, Texas
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: